The global chemotherapy-induced thrombocytopenia market size was valued at USD 1.71 billion in 2025 and is projected to grow from USD 1.81 billion in 2026 to USD 2.86 billion by 2034, registering a CAGR of 5.89% during the forecast period (2026-2034). North America dominated the chemotherapy-induced thrombocytopenia market with a share of 42.23% in 2025.
The chemotherapy-induced thrombocytopenia market includes medicines and supportive treatments used to manage low platelet counts caused by chemotherapy. Chemotherapy-induced thrombocytopenia treatments are commonly classified under HSN Code 3004 (medicaments in measured doses or retail packaging) and SIC Code 2834 (Pharmaceutical Preparations).
The chemotherapy-induced thrombocytopenia market demand is driven by the need to manage chemotherapy-related platelet decline and reduce bleeding complications. Healthcare providers are using thrombopoietin receptor agonists and supportive platelet management treatments.
Download a Free Sample To learn more about this report,
Shift toward Proactive Platelet Count Monitoring During Chemotherapy
The chemotherapy induced thrombocytopenia market analysis shows shift towards proactive platelet count monitoring to identify declining platelet levels before serious complications develop. Regular complete blood count testing helps supporting oncology teams assess treatment related platelet suppression, evaluate bleeding risks, and determine whether chemotherapy schedules or supportive treatments require adjustment.
Development of Novel Therapies to Stimulate Platelet Production
Research into the chemotherapy induced thrombocytopenia market is increasingly focused on therapies that stimulate platelet production and support recovery after chemotherapy. Thrombopoietin receptor agonists, which activate pathways involved in platelet formation, are being evaluated or used in selected clinical settings to address low platelet counts.
Supply chain disruptions are expected to have a moderate impact on the chemotherapy induced thrombocytopenia market share due to dependence on active pharmaceutical ingredients, drug formulations, and sterile packaging. The market is expected to follow a stair-step recovery, as shortages of pharmaceutical ingredients, manufacturing delays, and distribution constraints can affect the availability of platelet-supporting treatments. The market is expected to grow at a CAGR of 5.89%, but supply chain constraints could lower this by 0.8 percentage points, resulting in a growth of around 5.09%. As supply conditions normalize, the chemotherapy induced thrombocytopenia market growth is expected to gradually return to 5.89%.
The chemotherapy-induced thrombocytopenia market forecasts strategic investment activity driven by advancement of hetrombopag into global Phase III clinical trials, increased investment requirements for late-stage oncology research. In May 2026, Jiangsu Hengrui Pharmaceuticals initiated a global Phase III trial of hetrombopag for chemotherapy-induced thrombocytopenia, targeting 121 participants across five European countries. Although the company did not disclose the trial budget, the Tufts Center for the Study of Drug Development reported that average budgets exceed USD 65 million for Phase III oncology protocols.
Adoption of Personalized Supportive Cancer Care and Advancements in Thrombopoietin Receptor Agonists Drives Market
Personalized supportive cancer care focuses on managing treatment-related complications according to patients’ clinical conditions and chemotherapy risks. Individualized monitoring of platelet counts helps healthcare providers identify patients who may require thrombocytopenia management, increasing the need for appropriate supportive treatments and contributing to chemotherapy-induced thrombocytopenia market growth.
Advances in thrombopoietin receptor agonists are expanding treatment options for stimulating platelet production in selected patients with chemotherapy-induced thrombocytopenia. These therapies can help address low platelet counts and may support chemotherapy continuation when clinically appropriate. Continued research into their safety and effectiveness is strengthening interest in targeted treatment approaches for managing chemotherapy-related platelet decline.
Risk of Adverse Effects from Thrombopoietin Receptor Agonists and Challenges in Predicting Platelet Count Decline Restraints Market Expansion
Thrombopoietin receptor agonists used to manage chemotherapy-induced thrombocytopenia may cause adverse effects, including an increased risk of blood clots in certain patients. These risks require careful patient selection, dose adjustments, and regular monitoring, particularly among cancer patients who already have an elevated risk of thrombosis. Safety concerns may limit the use of these therapies in some cases and increase the complexity of treatment management.
Predicting platelet count decline during chemotherapy is challenging because patients respond differently to treatment based on cancer type, chemotherapy regimen, baseline platelet levels, and overall health. Unexpected declines can delay the identification of thrombocytopenia and make it difficult to determine when preventive treatment or supportive care is needed.
Expansion of Thrombopoietin Receptor Agonists for Chemotherapy Induced Thrombocytopenia and Home-Based Monitoring Offers Growth Opportunities
Pharmaceutical companies can target cancer patients who develop low platelet counts during chemotherapy by developing treatments that stimulate platelet production. Revenue opportunities include prescription drug sales, development of new therapeutic candidates, and partnerships with oncology care providers, contributing to chemotherapy-induced thrombocytopenia market growth.
Healthcare service providers and digital health companies can target cancer patients who require continued monitoring after chemotherapy sessions. Remote follow-up programs can help care teams track symptoms and coordinate blood test appointments. Market players can bank on digital care platforms and service agreements with oncology clinics, contributing to chemotherapy-induced thrombocytopenia market growth.
Thrombopoietin receptor agonists accounted for the largest share of 44.6%, supported by the use of these therapies to stimulate platelet production in patients experiencing chemotherapy-induced thrombocytopenia.
Thrombopoietin mimetics are likely to grow at a CAGR of 5.92% during the forecast period, driven by continued interest in therapies that stimulate platelet production. These agents support the management of reduced platelet counts in patients receiving chemotherapy.
Request Customizationto receive a tailored report.
Grade 2 segment held the leading position with a 31.8% share, reflecting the occurrence of moderate platelet count reductions during chemotherapy. Patients in this category may require regular blood count monitoring and treatment adjustments to manage thrombocytopenia while maintaining their cancer treatment schedules.
Grade 4 segment is projected to grow at a CAGR of 6.43% during the forecast period, driven by the need to manage severe thrombocytopenia and its associated bleeding risks.
Hospital pharmacies represented the largest share at 52.6%, supported by the administration and monitoring of cancer treatments and related supportive medications in hospital settings. Hospital pharmacies help coordinate access to prescribed therapies for patients whose platelet counts require close clinical supervision.
Specialty pharmacies will expand to 6.47% CAGR during the forecast period, fueled by the need for coordinated medication access and ongoing support for patients receiving complex cancer therapies.
Speak to an Analystto discuss market opportunities.
The North America chemotherapy-induced thrombocytopenia market accounted for a dominant share of 42.23% in 2025.
In the United States, research published demonstrated the potential of romiplostim, a thrombopoietin receptor agonist, to manage chemotherapy-induced thrombocytopenia. In a clinical trial involving 165 patients with cancer, 84% of patients receiving romiplostim avoided chemotherapy dose reductions, compared with 36% in the placebo group. These findings highlight the potential of platelet-count management therapies to help patients maintain planned cancer treatment schedules.
Canada’s participation in clinical research on chemotherapy-induced thrombocytopenia supports the evaluation of strategies to manage low platelet counts during cancer treatment. Guidance from the International Society on Thrombosis and Haemostasis, which includes Canadian hematology expertise, discusses thrombopoietin receptor agonists and platelet transfusion strategies for affected patients.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific chemotherapy-induced thrombocytopenia market is projected to grow at a CAGR of 7.11% during the forecast period, making it the fastest-growing region.
China’s Consensus on the Clinical Diagnosis, Treatment and Prevention of Cancer Treatment-Induced Thrombocytopenia outlines approaches to managing chemotherapy side effects that reduce platelet counts. The recommendations include platelet transfusions and platelet-stimulating therapies, including thrombopoietin receptor agonists (TPO-RAs), to address bleeding risks and support the continuation of planned cancer treatment.
A retrospective study conducted at Regency Hospital in Kanpur evaluated romiplostim, a thrombopoietin receptor agonist (TPO-RA), in 100 patients with chemotherapy-induced thrombocytopenia. The study reported significant increases in platelet counts among patients receiving romiplostim alone or alongside platelet transfusions, highlighting its potential role in managing chemotherapy-related platelet depletion and supporting continued cancer treatment.
Japan’s oncology sector is evaluating approaches to prevent chemotherapy-related declines in platelet counts and reduce treatment interruptions. The use of platelet-count monitoring alongside supportive interventions, including platelet transfusions and emerging TPO-RA therapies, highlights the clinical need to manage thrombocytopenia in patients receiving myelosuppressive cancer treatment.
Europe's chemotherapy-induced thrombocytopenia market is expected to achieve a growth rate of 5.61% during the forecast period.
A multicenter clinical trial conducted at eight German hematology centres evaluated therapeutic versus prophylactic platelet transfusion in patients receiving intensive chemotherapy for acute myeloid leukemia or undergoing autologous stem cell transplantation. The study examined whether transfusions triggered by bleeding could reduce transfusion use compared with routine preventive transfusions.
A UK-based phase III clinical trial, TOPPS, investigated whether prophylactic platelet transfusions reduced bleeding in patients with hematological cancers or undergoing stem-cell transplantation. The findings showed that routine prophylactic transfusions did not provide the same benefit across all patient groups, highlighting the importance of individualised platelet support and bleeding-risk assessment in oncology supportive care.
The Latin America chemotherapy-induced thrombocytopenia market is expected to experience a growth rate of CAGR of 5.73% during the forecast period. Researchers at the University of Campinas in Brazil published a study examining platelet counts in patients with hematological malignancies who developed febrile neutropenia after chemotherapy. The study investigated the association between platelet levels and mortality, highlighting the clinical importance of monitoring thrombocytopenia during cancer treatment.
Mexico’s Federal Commission for the Protection against Sanitary Risks (COFEPRIS) authorised a Phase III clinical trial of romiplostim, a thrombopoietin receptor agonist (TPO-RA), for chemotherapy-induced thrombocytopenia in patients receiving treatment for gastrointestinal and colorectal cancers.
The Middle East & Africa chemotherapy-induced thrombocytopenia market will expand at a CAGR of 5.35% during the forecast period. The UAE is strengthening specialized cancer care through the Ministry of Health and Prevention’s Ministerial Resolution No. 25, which establishes multidisciplinary medical committees to evaluate cancer cases and develop individualized treatment plans.
South Africa’s National Cancer Strategic Framework identifies gaps in equitable access to cancer diagnosis, treatment, and supportive care, including the need to strengthen services across different levels of the healthcare system.
The chemotherapy-induced thrombocytopenia market competitive landscape is highly fragmented, with established pharmaceutical companies and specialized supportive care therapy providers. Key players such as Amgen, Novartis, Swedish Orphan Biovitrum, Shionogi & Co., and Kyowa Kirin are estimated to account for 30–35% of the global chemotherapy-induced thrombocytopenia market share.
Established players compete mainly through platelet-stimulating therapies, treatment efficacy, drug safety, and supportive care solutions for cancer patients. Emerging and regional players in the chemotherapy-induced thrombocytopenia market ecosystem focus on novel thrombopoietin receptor agonists and application-specific therapies to manage chemotherapy-related platelet count reductions.
May 2026: Jiangsu Hengrui Pharmaceuticals presented its global Phase III study of hetrombopag for chemotherapy-induced thrombocytopenia.
March 2026: Amgen and the US Biomedical Advanced Research and Development Authority (BARDA) reported Phase III results for romiplostim (Nplate) in persistent chemotherapy-induced thrombocytopenia.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Experts
The Straits Research Team is a group of experienced researchers, analysts, and industry professionals dedicated to delivering reliable, insightful, and well-structured market intelligence. With expertise across multiple sectors and domains, the team combines extensive research, data analysis, and industry knowledge to provide a clear understanding of evolving markets and business environments.
The team focuses on identifying key market trends, emerging opportunities, technological developments, competitive landscapes, and changing industry dynamics. Through a thoughtful and research-driven approach, it aims to provide valuable insights that help businesses, investors, and decision-makers better understand their industries and make informed strategic decisions.
Autosomal Dominant Polycystic Kidney Disease Market Size, Forecast, 2034
Ovarian Cancer Market Size, Share, Growth, Analysis, Report, 2034
Chronic Venous Occlusions Treatment Market Size, Demand, Opportunities, 2034
Cardiometabolic Disease Market Size, Share, Growth, Analysis, 2034
Clot Busting Drugs Market Size, Forecast, Demand, Opportunities, 2034
Antibody Drug Conjugates Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com